Direkt zum Inhalt
Merck
  • Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines.

Prevalence and correlates of treatment failure among Kenyan children hospitalised with severe community-acquired pneumonia: a prospective study of the clinical effectiveness of WHO pneumonia case management guidelines.

Tropical medicine & international health : TM & IH (2014-08-19)
Ambrose Agweyu, Minnie Kibore, Lina Digolo, Caroline Kosgei, Virginia Maina, Samson Mugane, Sarah Muma, John Wachira, Mary Waiyego, Elizabeth Maleche-Obimbo
ZUSAMMENFASSUNG

To determine the extent and pattern of treatment failure (TF) among children hospitalised with community-acquired pneumonia at a large tertiary hospital in Kenya. We followed up children aged 2-59 months with WHO-defined severe pneumonia (SP) and very severe pneumonia (VSP) for up to 5 days for TF using two definitions: (i) documentation of pre-defined clinical signs resulting in change of treatment (ii) primary clinician's decision to change treatment with or without documentation of the same pre-defined clinical signs. We enrolled 385 children. The risk of TF varied between 1.8% (95% CI 0.4-5.1) and 12.4% (95% CI 7.9-18.4) for SP and 21.4% (95% CI 15.9-27) and 39.3% (95% CI 32.5-46.4) for VSP depending on the definition applied. Higher rates were associated with early changes in therapy by clinician in the absence of an obvious clinical rationale. Non-adherence to treatment guidelines was observed for 70/169 (41.4%) and 67/201 (33.3%) of children with SP and VSP, respectively. Among children with SP, adherence to treatment guidelines was associated with the presence of wheeze on initial assessment (P = 0.02), while clinician non-adherence to guideline-recommended treatments for VSP tended to occur in children with altered consciousness (P < 0.001). Using propensity score matching to account for imbalance in the distribution of baseline clinical characteristics among children with VSP revealed no difference in TF between those treated with the guideline-recommended regimen vs. more costly broad-spectrum alternatives [risk difference 0.37 (95% CI -0.84 to 0.51)]. Before revising current pneumonia case management guidelines, standardised definitions of TF and appropriate studies of treatment effectiveness of alternative regimens are required.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Amoxicillin, 95.0-102.0% anhydrous basis
USP
Amoxicillin, United States Pharmacopeia (USP) Reference Standard
Supelco
Amoxicillin Trihydrat, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Amoxicillin Trihydrat, VETRANAL®, analytical standard
Amoxicillin Trihydrat, European Pharmacopoeia (EP) Reference Standard
Amoxicillin-Trihydrat für die Leistungsverifizierung, European Pharmacopoeia (EP) Reference Standard